NEW YORK: Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, resilience-based, connected health solution for chronic condition management, announced the launch of its Direct-to-Consumer (DTC) offering in the New York tri-state area for people living with Crohn’s Disease and ulcerative colitis.
The Company’s DTC service will provide its resilience-based methodology to support adult IBD patients’ clinical treatment plans through care coordination, behavioral skills training, expert disease education and remote patient monitoring.
The program includes personalized whole-person care plans, the HIPAA-compliant TrellusElevate digital platform, telehealth services and remote access to an expert licensed care team including a nurse educator, behavioral health counselor, dietitian and resilience coach.
Initially, Trellus Health will offer enrollment for patients over age 17 in the states of New York, New Jersey and Connecticut, with plans to expand into more than twenty states by the end of the year. With over 30 million residents, the New York tri-state area contains one of the highest concentrations of people living with IBD in the United States (c.250,000 patients).
Trellus Health partners with Connected Health Medicine PC to deliver telehealth clinical services using licensed healthcare professionals. Fees to access and engage with the Company’s DTC service will be paid directly by patients or reimbursed by health insurance using existing current procedural terminology (CPT) codes with select commercial insurance plans.
Direct-to-Consumer (DTC) pricing is lower on average than value-based B2B contract fees, and a discounted introductory monthly membership rate is being offered to build rapid awareness and recruitment.
As previously stated in the Company’s trading update from December 2021, the focus for 2022 will be on recruitment of DTC patients and the establishment of additional demonstration programs and B2B contracts. This will enable Trellus to gather real world evidence to validate and reinforce the health quality and economic outcomes shown in the co-founders’ published research, as well as informing further product development.
Recently published clinical research demonstrated that IBD patients show significant improvements in resilience and reductions in expensive unplanned healthcare usage by utilising the GRITTTM methodology and multidisciplinary care model that was exclusively licensed from the Icahn School of Medicine at Mount Sinai. As greater evidence is amassed in 2022, the Company expects to enter regional and national multi-year contracts with US employers and health insurance payers from 2023 onwards.
Monique Fayad, CEO of Trellus Health, said: “We are pleased to announce the launch of our Direct-to-Consumer membership for adults living with IBD in the New York tri-state area. Our DTC offering will accelerate patient recruitment, which is expected to make a material contribution to the number of patients under management via the TrellusElevate platform by the end of 2022.
“IBD is a debilitating, incurable condition that requires behavioral support to cope with the complexity and challenges of daily living. Trellus Health partners with IBD patients and their GI Providers, offering behavioral, nutritional and clinical monitoring support and tools beyond traditional episodic medical care, with the goal of empowering patients, improving outcomes and reducing the need for unplanned hospital and emergency room visits. Healthcare providers can look to Trellus as a trusted extension of their gastroentrology practice that helps improve care plan adherence and outcomes through remote patient monitoring and access to much needed whole-person care.”
